Author

J. Rodon

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6 Cancer Biology· 1 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 8 Research Focus:drug response / drug discovery· 5 Research Focus:host-pathogen & immune response· 4 Organism:human· 3 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 1 Organism:multiple species· 1

Frequent Co-Authors

J. Segales· 7 shared J. Vergara-Alert· 7 shared B. Clotet· 5 shared J. Blanco· 5 shared A. Valencia· 4 shared J. Carrillo· 4 shared M. Perez· 4 shared N. Izquierdo-Useros· 4 shared

Activity by Year

2017-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersImmunology

J. Segales

Mutual co-authors in cluster

Author profile →

9 papers

Recent·Most cited

Novel Spike-stabilized trimers with improved production protect K18-hACE2 mice and golden Syrian hamsters from the highly pathogenic SARS-CoV-2 Beta variant.

J. Carrillo, C. Avila-Nieto, J. Vergara-Alert, P. Amengual-Rigo, E. Ainsua-Enrich, M. Brustolin, M. L. Rodriguez de la Concepcion, N. Pedreno-Lopez, J. Rodon, V. Urrea, E. Pradenas, S. Marfil, E. Ballana, E. Riveira-Munoz, M. Perez, , J. Segales

This paper identifies mutations that improve the production and efficacy of SARS-CoV-2 Spike proteins, protecting animal models from the Beta variant.

bioRxiv · Jul 7, 2023Immunology

High-throughput quantification of camelid cytokine mRNA expression in PBMCs by microfluidic qPCR technology

J. Rodon, N. Te, M. Ballester, J. Segales, J. Vergara-Alert, A. Bensaid

The paper develops RT-qPCR assays to quantify immune response genes in camelid PBMCs and identifies species-specific cytokine responses to stimulations.

bioRxiv · Jan 15, 2023 · PreprintImmunology

Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

A. Barreiro, A. Prenafeta, G. Bech-Sabat, M. Roca, E. Perozo, R. March, L. Gonzalez-Gonzalez, L. Madrenas, J. Corominas, A. Fernandez, A. Moros, M. Molas, T. Pentinat-Pelegrin, C. Panosa, A. Moreno, , Barr

This paper evaluates a recombinant RBD fusion heterodimer vaccine in mice, showing 100% efficacy against SARS-CoV-2 variants and neutralizing antibodies.

bioRxiv · Nov 22, 2021Immunology

Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in hamsters

M. Brustolin, J. Rodon, M. L. Rodriguez de la Concepcion, C. Avila-Nieto, G. Cantero, M. Perez, T. Nigeer, M. Noguera-Julian, V. Guallar, A. Valencia, N. Roca, N. Izquierdo-Useros, J. Blanco, B. Clotet, A. Bensaid, , J. Segales

This study shows that hamsters infected with SARS-CoV-2 are not fully protected against reinfection with both original and variant isolates, but experience reduced lung disease severity upon re-exposure.

bioRxiv · Jan 7, 2021 · PreprintPathology

Type I and III IFNs produced by the nasal epithelia and dimmed inflammation are key features of alpacas resolving MERS-CoV infection

N. Te, J. Rodon, M. Ballester, M. Perez, L. Pailler-Garcia, J. Segales, J. Vergara-Alert, A. Bensaid

This study identifies type I and III IFNs in nasal mucosa and anti-inflammatory responses as key to alpacas resolving MERS-CoV infection without severe symptoms.

bioRxiv · Nov 23, 2020Immunology

Stable neutralizing antibody levels six months after mild and severe COVID-19 episode

E. Pradenas, B. Trinite, V. Urrea, S. Marfil, C. Avila-Nieto, M. L. Rodriguez de la Concepcion, F. Tarres-Freixas, S. Perez-Yanes, C. Rovirosa, E. Ainsua-Enrich, J. Rodon, J. Vergara-Alert, J. Sagales, V. Guallar, A. Valencia, , J. Blanco

This study tracks neutralizing antibody levels in COVID-19 patients up to six months post-infection, finding persistent activity in mild cases and a slower decline in hospitalized individuals.

bioRxiv · Nov 22, 2020Immunology

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

J. M. Diez, C. Romero, J. Vergara Alert, M. Bello Perez, J. Rodon, J. M. Honrubia, J. Segales, I. Sola, L. Enjuanes, R. Gajardo

This study shows that currently available IVIG products neutralize SARS-CoV-2 and SARS-CoV in cell cultures but not MERS-CoV.

bioRxiv · Jun 19, 2020Immunology

Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect after a Drug Repurposing Screen

J. Rodon, J. Munoz-Basagoiti, D. Perez-Zsolt, M. Noguera-Julian, R. Paredes, L. Mateu, C. Quinones, I. Erkizia, I. Blanco, A. Valencia, V. Guallar, J. Carrillo, J. Blanco, J. Segales, B. Clotet, , N. Izquierdo-Useros

This study screens existing drugs to identify potent inhibitors of SARS-CoV-2-induced cytopathic effect and viral replication, finding plitidepsin as the most effective clinically approved drug.

bioRxiv · Apr 23, 2020 · PreprintMicrobiology

Cancer Genome Interpreter Annotates The Biological And Clinical Relevance Of Tumor Alterations

D. Tamborero, C. Rubio-Perez, J. Deu-Pons, M. P. Schroeder, A. Vivancos, A. Rovira, I. Tusquets, J. Albanell, J. Rodon, J. Tabernero, C. de Torres, R. Dienstmann, A. Gonzalez-Perez, N. Lopez-Bigas

The paper introduces a tool to annotate and interpret the biological and clinical relevance of tumor genomic alterations.

bioRxiv · Jun 21, 2017Cancer Biology